A blood draw that argues with the calendar
A vial of blood sits in a centrifuge in Seattle. Nothing about it looks dramatic. But AltPep is betting it can read that vial and tell you something your body has not yet admitted: that a disease is forming, quietly, years before a single symptom shows up. That is the whole company in one image - a small sample, a very old molecular problem, and a stubborn refusal to wait for the obvious.
AltPep is a Seattle biotechnology company building two things at once. A test that finds the earliest signature of amyloid disease, and a drug designed to neutralize it. Most companies pick a lane. AltPep decided the diagnosis and the cure were the same conversation, just told from two ends.
By the time you can see it, it is late
Here is the uncomfortable truth about Alzheimer's. By the time a person forgets names, loses their keys with a new kind of fear, and finally gets a diagnosis, the damage in the brain has been accumulating for a decade or more. The standard tools - PET scans hunting for plaques, spinal taps, cognitive tests - mostly confirm what is already well underway. They are very good at telling you the house is on fire. They are not built to smell the smoke.
Roughly six million Americans live with Alzheimer's today. That number is projected to reach thirteen million by 2050. For most of that history, the field chased plaques - the visible clumps. AltPep's founding premise is that the plaques are the wreckage, not the trigger.
A protein shape that lived in a computer for years
Valerie Daggett spent decades at the University of Washington running molecular-dynamics simulations of how proteins fold and misfold. Somewhere in that work, her lab predicted a structure nobody had catalogued before: the alpha-sheet. It was, for a long time, a theoretical curiosity - a shape that existed mostly inside a simulation, waiting for someone to decide it mattered.
It turned out to matter quite a lot. The alpha-sheet appears in the toxic soluble oligomers that form early in amyloid diseases - small, slippery, pre-plaque assemblies that may be the actual agents of harm. The same culprit links diseases as different as Alzheimer's, Parkinson's, and type 2 diabetes. In 2019, Daggett spun AltPep out of her lab to turn that insight into products. The company name is a quiet wink at the science: "Alt" for alpha-sheet, "Pep" for the custom peptides it designs.
One culprit, two instruments
Once you believe the toxic oligomer is the thing to chase, the product strategy writes itself. You need to find it, and you need to disarm it. AltPep designed synthetic peptides to do both, which is a tidy bit of engineering symmetry that the disease itself does not deserve.
SOBA
The Soluble Oligomer Binding Assay - a blood test that detects toxic alpha-sheet oligomers. Lead version SOBA-AD targets Alzheimer's.
SOBIN
The Soluble Oligomer Binding INhibitor - custom peptide therapeutics designed to bind and neutralize the oligomers. SOBIN-AD and SOBIN-PD lead the pipeline.
Alpha-sheet platform
The design engine underneath both - a non-standard protein structure used to rationally build detection and treatment across many amyloid diseases.
It is the rare biotech that builds both the smoke detector and the fire extinguisher. AltPep's pitch is that the two share a target, so progress on one informs the other.
How AltPep got here
A timeline assembled from press releases, regulatory filings, and one very patient research lab.
Spun out of UW
AltPep launches from Valerie Daggett's bioengineering lab at the University of Washington.
$23M Series A
First major round to push detection and treatment programs forward.
FDA Breakthrough Device
SOBA-AD blood test earns Breakthrough Device designation, unlocking prioritized review.
Toxic oligomers, years early
Published data shows the blood test detecting toxic amyloid before symptoms appear.
$52.9M Series B
Senator Investment Group leads, with Section 32, Partners Investment and Eli Lilly joining.
Nature publication
Scientific Reports study further affirms SOBA-AD's potential to detect Alzheimer's.
Therapeutic data
Presents preclinical SOBIN-AD results at major Alzheimer's conferences.
The numbers that earned the meetings
Skepticism is the correct posture toward any company promising to detect a disease before it shows itself. So here is the part that made investors and regulators lean in. In a study published in Nature's Scientific Reports, the SOBA-AD blood test separated Alzheimer's patients from cognitively unimpaired people with numbers that are unusually clean for early diagnostics.
SOBA-AD study performance
From a Nature Scientific Reports study. Higher is better, and these are about as high as the chart goes.
Proof is not only clinical. It is also who shows up with a checkbook. AltPep has raised more than $120 million across its rounds, and the Series B drew Eli Lilly - a company that makes its own Alzheimer's drugs and presumably knows a credible approach when it sees one.
Move the moment of action up by years
Every disease has a clock. AltPep's entire reason for existing is to read that clock earlier - to turn a diagnosis that usually arrives after the damage into one that arrives before it. That is a different kind of medicine. It asks doctors to act on a signal, not a symptom, and it asks patients to confront a risk they cannot yet feel.
The diagnostics-plus-therapeutics combination is the strategy that makes that ambition coherent. A test that finds the trigger is more useful when there is a drug aimed at the same trigger. A drug is easier to deploy when a test can say who needs it and whether it is working. SOBA and SOBIN are two halves of one argument.
Things worth knowing about AltPep
- The alpha-sheet was predicted by simulation long before it became a product - a structure that lived in a computer for years.
- The same toxic-oligomer culprit links Alzheimer's, Parkinson's, and type 2 diabetes.
- The company name is a clue: "Alt" for alpha-sheet, "Pep" for the custom peptides it designs.
- Eli Lilly, itself a maker of Alzheimer's drugs, invested in AltPep's Series B.
- AltPep builds both the smoke detector and the fire extinguisher: SOBA finds, SOBIN fights.
Back to the vial in the centrifuge
Return to that small vial of blood spinning in a Seattle lab. A few years ago, it would have told you almost nothing useful about a brain that is just beginning to go wrong. AltPep's wager is that the same vial can now carry a verdict the old tools could not read - that the disease is starting, and there is still time.
Nothing here is finished. The therapeutics are heading toward early clinical trials, not pharmacy shelves. The test still has a regulatory road ahead. The skeptic's questions remain fair ones. But the shape of the bet is clear, and increasingly hard to dismiss: find the trigger, design a peptide that knows it by sight, and move the entire fight against amyloid disease years earlier than anyone expected to fight it.
That vial does not look dramatic. AltPep is the reason it might be.
Find AltPep
Watch & learn: search "Valerie Daggett alpha-sheet" on YouTube for lab talks and explainers on the science behind SOBA and SOBIN. A dedicated product demo video was not publicly listed at publication time.